The Europe Uveitis Treatment Market would witness market growth of 5.02% CAGR during the forecast period (2019-2025). For the treatment of infectious uveitis, certain medications have advantages over others. Topical and systemic treatments are often used in the treatment of ocular infection, but the treatment route may be limited by penetration, concentration, and duration. The advent of antimicrobial intravitreal therapy has furthered the treatment of intraocular infections. With limited systemic absorption, being able to overcome blood-ocular barriers allows for large concentrations of drugs to be administered directly to the posterior section. Nevertheless, because the difference between the therapeutic and toxic doses of certain antimicrobial drugs falls within a small range of concentration, intravitreal therapy can be associated with risks of ocular toxicity.
Intermediate uveitis is a vitreous and peripheral retina-localized type of uveitis. Primary inflammatory sites include the vitreous which includes other entities such as pars planitis, posterior cyclitis, and hyalitis. Intermediate uveitis may be either an isolated eye disease or related to the development of a systemic condition such as multiple sclerosis or sarcoidosis. As such, the first manifestation of a systemic disorder may be intermediate uveitis. Infectious causes of intermediate uveitis include infection with the Epstein-Barr virus, Lyme disease, HTLV-1 virus, cat scratch disease, and hepatitis C.
Based on Drug Class, the market is segmented into Anti-inflammatory, Immunotherapy & Targeted Therapies, Antimicrobial Drugs and Other Drug Class. Based on Disease Type, the market is segmented into Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis and Panuveitis. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online stores. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: Uveitis Treatment Market in Europe is expected to register a CAGR of 5.02% during the forecast period (2019-2025)
The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Alimera Sciences, Inc., Enzo Biochem, Inc., Amgen, Inc., Bausch Health Companies, Inc., Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., TopiVert Ltd., and Novartis AG.
Market Segmentation:
By Drug Class
By Disease Type
By Distribution Channel
By Country
Companies Profiled
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
